Photo from wikipedia
The elevated risk of adverse events following percutaneous coronary intervention in diabetic patients persists with newer‐generation DES. The polymer‐free amphilimus‐eluting stent (PF‐AES) possesses characteristics with a potentially enhanced performance in… Click to show full abstract
The elevated risk of adverse events following percutaneous coronary intervention in diabetic patients persists with newer‐generation DES. The polymer‐free amphilimus‐eluting stent (PF‐AES) possesses characteristics with a potentially enhanced performance in patients with diabetes. Data from the 1‐year follow‐up period has been previously published. The aim of this subanalysis was to assess long‐term performance of two contemporary drug‐eluting stents (DES) in a diabetic population.
Journal Title: Catheterization and Cardiovascular Interventions
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!